Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $2.19B | $2B | +9.50% |
Cost of Revenue | $643M | $588M | +9.35% |
Net Income | $599M | $552M | +8.51% |
EPS (Basic) | $1.31 | $1.19 | +10.08% |
EPS (Diluted) | $1.31 | $1.19 | +10.08% |
SG&A Expense | $547M | $505M | +8.32% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $14.35B | $13.75B | +4.32% |
Current Assets | $6.36B | $6.27B | +1.44% |
Total Liabilities | $9.3B | $9.26B | +0.36% |
Current Liabilities | $1.91B | $1.92B | -0.31% |
Stockholders' Equity | $5.06B | $4.49B | +12.55% |
Cash & Equivalents | $1.98B | $2.11B | -6.35% |
Long-Term Debt | $6.56B | $6.56B | +0.05% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $595M | $549M | +8.38% |
Investing Cash Flow | $-131M | $-216M | +39.35% |
Financing Cash Flow | $-524M | $-1.8B | +70.92% |
Share Buybacks | $339M | $283M | +19.79% |
D&A | $126M | $120M | +5.00% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 27.4% | — | — |
ROE | 11.8% | — | — |
ROA | 4.2% | — | — |
Current Ratio | $3.331 | — | — |
Debt to Equity | $1.838 | — | — |
Other companies in Pharmaceuticals